利用北欧人群历史:发现多囊卵巢综合征新的低频变异
基于芬兰和爱沙尼亚人群的病例对照全基因组关联研究,发现三个与多囊卵巢综合征(PCOS)全基因组显著相关的新变异,其中两个位于CHEK2基因,一个位于MYO10附近,并重复了四个既往报道的关联。
要点
- 发现CHEK2基因两个新变异与PCOS相关:rs145598156(OR=3.01)和rs182075939(OR=1.69),在芬兰和爱沙尼亚人群中富集。
- 发现MYO10附近常见变异rs9312937与PCOS相关(OR=1.16)。
- 重复了ERBB4、DENND1A、FSHB和ZBTB16附近的四个既往关联。
核心结论
- 通过利用北欧人群历史,识别出三个与PCOS全基因组显著相关的新变异,分别位于CHEK2和MYO10。
研究设计与样本
- 基于人群的病例对照全基因组关联研究。
- 发现阶段纳入FinnGen研究的797例病例和140558例对照。
- 验证阶段使用爱沙尼亚生物库的2812例病例和89230例对照。
- 联合荟萃分析纳入两个队列共3609例病例和229788例对照。
- 另以BMI为协变量重新运行关联分析,纳入两个队列2169例病例和160321例对照。
主要发现
- rs145598156与PCOS相关(P=3.6×10-8,OR=3.01 [2.02-4.50],MAF=0.005),与CHEK2的c.1100delC缺失紧密连锁(r2=0.95)。
- rs182075939与PCOS相关(P=1.9×10-16,OR=1.69 [1.49-1.91],MAF=0.04),与CHEK2的错义变异I157T紧密连锁(r2=0.83)。
- rs9312937(位于MYO10附近)与PCOS相关(P=1.7×10-8,OR=1.16 [1.10-1.23],MAF=0.44)。
- 重复了ERBB4、DENND1A、FSHB和ZBTB16附近的四个既往关联。
- 以BMI为协变量后,荟萃分析中仅CHEK2的rs182075939保持全基因组显著(P=1.9×10-16,OR=1.74 [1.5-2.01])。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 主要局限性是PCOS在登记系统中的患病率低,但确诊者很可能代表最严重的病例。
- BMI数据并非全部可得(FinnGen为63%,EstBB为76%)。
- 生物库设置限制了对PCOS表型和实验室值的可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can we identify novel variants associated with polycystic ovary syndrome (PCOS) by leveraging the unique population history of Northern Europe? SUMMARY ANSWER: We identified three novel genome-wide significant associations with PCOS, with two putative independent causal variants in the checkpoint kinase 2 (CHEK2) gene and a third in myosin X (MYO10). WHAT IS KNOWN ALREADY: PCOS is a common, complex disorder with unknown aetiology. While previous genome-wide association studies (GWAS) have mapped several loci associated with PCOS, the analysis of populations with unique population history and genetic makeup has the potential to uncover new low-frequency variants with larger effects. STUDY DESIGN, SIZE, DURATION: A population-based case-control GWAS was carried out. PARTICIPANTS/MATERIALS, SETTING, METHODS: We identified PCOS cases from national registers by ICD codes (ICD-10 E28.2, ICD-9 256.4, or ICD-8 256.90), and all remaining women were considered controls. We then conducted a three-stage case-control GWAS: in the discovery phase, we had a total of 797 cases and 140 558 controls from the FinnGen study. For validation, we used an independent dataset from the Estonian Biobank, including 2812 cases and 89 230 controls. Finally, we performed a joint meta-analysis of 3609 cases and 229 788 controls from both cohorts. Additionally, we reran the association analyses including BMI as a covariate, with 2169 cases and 160 321 controls from both cohorts. MAIN RESULTS AND THE ROLE OF CHANCE: Two out of the three novel genome-wide significant variants associating with PCOS, rs145598156 (P = 3.6×10-8, odds ratio (OR) = 3.01 [2.02-4.50] minor allele frequency (MAF) = 0.005) and rs182075939 (P = 1.9×10-16, OR = 1.69 [1.49-1.91], MAF = 0.04), were found to be enriched in the Finnish and Estonian populations and are tightly linked to a deletion c.1100delC (r2 = 0.95) and a missense I157T (r2 = 0.83) in CHEK2. The third novel association is a common variant near MYO10 (rs9312937, P = 1.7 × 10-8, OR = 1.16 [1.10-1.23], MAF = 0.44). We also replicated four previous reported associations near the genes Erb-B2 Receptor Tyrosine Kinase 4 (ERBB4), DENN Domain Containing 1A (DENND1A), FSH Subunit Beta (FSHB) and Zinc Finger And BTB Domain Containing 16 (ZBTB16). When adding BMI as a covariate only one of the novel variants remained genome-wide significant in the meta-analysis (the EstBB lead signal in CHEK2 rs182075939, P = 1.9×10-16, OR = 1.74 [1.5-2.01]) possibly owing to reduced sample size. LARGE SCALE DATA: The age- and BMI-adjusted GWAS meta-analysis summary statistics are available for download from the GWAS Catalog with accession numbers GCST90044902 and GCST90044903. LIMITATIONS, REASONS FOR CAUTION: The main limitation was the low prevalence of PCOS in registers; however, the ones with the diagnosis most likely represent the most severe cases. Also, BMI data were not available for all (63% for FinnGen, 76% for EstBB), and the biobank setting limited the accessibility of PCOS phenotypes and laboratory values. WIDER IMPLICATIONS OF THE FINDINGS: This study encourages the use of isolated populations to perform genetic association studies for the identification of rare variants contributing to the genetic landscape of complex diseases such as PCOS. STUDY FUNDING/COMPETING INTEREST(S): This work has received funding from the European Union's Horizon 2020 research and innovation programme under the MATER Marie Skłodowska-Curie grant agreement No. 813707 (N.P.-G., T.L., T.P.), the Estonian Research Council grant (PRG687, T.L.), the Academy of Finland grants 315921 (T.P.), 321763 (T.P.), 297338 (J.K.), 307247 (J.K.), 344695 (H.L.), Novo Nordisk Foundation grant NNF17OC0026062 (J.K.), the Sigrid Juselius Foundation project grants (T.L., J.K., T.P.), Finska Läkaresällskapet (H.L.) and Jane and Aatos Erkko Foundation (H.L.). The funders had no role in study design, data collection and analysis, publishing or preparation of the manuscript. The authors declare no conflicts of interest.
引用
- Tyrmi JS, Arffman RK, Pujol-Gualdo N, et al. Leveraging Northern European population history: novel low-frequency variants for polycystic ovary syndrome. Hum Reprod. 2022. PMID: 34791234. doi:10.1093/humrep/deab250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。